PRESS RELEASE

Life Molecular Imaging announces presentation of new scientific data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2025

Research Presented Provides Further Insights into Amyloid and Tau PET Imaging

BERLIN, Germany, June 20 2025 – Life Molecular Imaging (LMI) announces today that new research results using its positron emission tomography (PET) imaging tracers will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans (June 21-24, 2025), where groundbreaking research meets clinical innovation.

Research abstracts involving LMI compounds florbetaben F18 injection and/or PI-2620 presented at the SNMMI conference include the following presentations:

FormatScheduleTitlePresenting authorDetails
1PresentationSaturday, 21 Jun 2025
2:10 – 2:20 PM
(Physics, Instrumentation & Data Sciences)		Pipeline Development for Cerebral Blood Flow and Binding Potential Quantification using a 20 min Dynamic 18F-Florbetaben PET ScanDanny De Sarno231-232 (Convention Center)
SS04: PIDSC: Data Analysis and Dosimetry
In-Person & On-Demand
2PresentationSunday, 22 Jun 2025
5:10 – 5:20 PM
(Neurosciences)		The First Human Brain PET Scans using PHAROS Multi-functional High-Resolution Digital PET System with DOI and TOF TechnologyJae Sung Lee208-209 (Convention Center)
IS_1
IS03: Kuhl-Lassen Award Session
In-Person & On-Demand
3PresentationMonday, 23 Jun 2025
2:45 – 3:30 PM
(Neurosciences)		Correlation of Early and Delayed [18F]FBB PET Imaging in Assessing Beta-Amyloid Deposition and Neurodegeneration in Alzheimer's DiseaseSeo Young KangHall B-C (Convention Center)
MTA08: Neuroscience
Science Pavilion
In-Person Only
4PresentationTuesday, 24 Jun 2025
8:30 – 9:15 AM
(Physics, Instrumentation & Data Sciences)		Single-Session Triple-Tracer Brain PET Imaging Using Deep LearningYiyi HuHall B-C (Convention Center) / MTA09
Science Pavilion
MTA09: Physics, Instrumentation & Data Sciences
In-Person Only
5PresentationTuesday, 24 Jun 2025
8:50 – 9:00 AM
(Neurosciences)		Amyloid PET Radiomics: Correlations with Clinical Features and Neurodegenerative Disease TypesTomoaki Otani225-227 (Convention Center)
SS_1
SS25: Clinical Neurosciences I
In-Person & On-Demand
6PresentationTuesday, 24 Jun 2025
1:00 – 1:45 PM
(Physics, Instrumentation & Data Sciences)		An Integrated Solution for Precision PET Brain Imaging: Motion Corrected, Regularized, and MR-GuidedMatthew Spangler-BickellHall B-C (Convention Center)
MTA11: Physics, Instrumentation & Data Sciences
Science Pavilion
In-Person Only
7PosterJune 21-24, 2025Comparison of Amyloid-PET Analysis Software Using 18F-florbetaben Brain PET/CT with Cognitive ImpairmentMiju CheonPoster area
8PosterJune 21-24, 2025Tau and Amyloid Biomarkers for Alzheimer’s Disease: A Dual-phase and Dual-modality PET Imaging Study with [18F]PI-2620 and [18F]florbetabenShichun PengPoster area
9PosterJune 21-24, 2025Molecular Imaging for Cardiac Amyloidosis: Opportunities and ChallengesAarti PandeyPoster area
10PosterJune 21-24, 2025Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Persons with Alzheimer's Disease: The Prospective CACAO-PET StudyStephan SettelmeierPoster area
11PosterJune 21-24, 2025Fully automated fast spatial normalization for multi-modality multi-tracer brain PET without MRI based on Cascaded Neural NetworksCheng TangPoster area

To learn more about the meeting, click here to visit the SNMMI Annual Meeting website: https://snmmi.org/AM/

To meet the LMI team, please visit booth #713 during SNMMI annual meeting in New Orleans.

About Neuraceq® (florbetaben 18F)

Indication
Neuraceq® is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq® scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq® scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq® is an adjunct to other diagnostic evaluations.

Limitations of Use

  • A positive Neuraceq® scan does not establish the diagnosis of AD or any other cognitive disorder.
  • Safety and effectiveness of Neuraceq® have not been established for:
    • Predicting development of dementia or other neurologic conditions
    • Monitoring responses to therapies.

Important Safety Information

Risk for Image Interpretation and Other Errors
Errors may occur in the Neuraceq® estimation of brain neuritic β-amyloid plaque density during image interpretation. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq® images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq® scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq® scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.

Radiation Risk
Neuraceq®, similar to other radiopharmaceuticals, contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure.

Common Adverse Reactions
The overall safety profile of Neuraceq® is based on data from 1,090 administrations of Neuraceq® to 872 subjects. No serious adverse reactions related to Neuraceq® administration have been reported. The most frequently observed adverse drug reactions in subjects receiving Neuraceq® were injection site reactions consisting of erythema (1.7%), irritation (1.1%) and pain (3.4%).

For more information please visit: Neuraceq.com

About PI-2620
Tau deposits, in conjunction with beta-amyloid plaques, represent the other pathological hallmark of Alzheimer’s disease, with tau deposits further playing an important role in other neurodegenerative diseases. PI-2620 is binding to 3R/4R and 4R tau deposits and is a next generation 18F-labeled investigational PET tracer with favorable properties and imaging characteristics. It was discovered in a research collaboration between Life Molecular Imaging and AC Immune, a Swiss-based clinical stage biopharmaceutical company. Life Molecular Imaging has the exclusive, world-wide license for research, development and commercialization of tau PET tracers generated within the discovery program.

About Life Molecular Imaging (LMI)
Life Molecular Imaging GmbH, together with its affiliates in the UK and US (LMI) is a radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. To learn more about LMI, please visit https://life-mi.com. LMI, a member of the Life Healthcare group of companies, is being acquired by Lantheus Holdings, Inc. For more information about the pending acquisition, please visit https://www.lifehealthcare.co.za/news-and-info-hub/latest-news/life-healthcare-proposed-disposal-of-lmi/.

For media queries
Brittany Hahn
Marketing Communications Manager
Life Molecular Imaging

Tel: +1.484.735.2840 |  b.hahn@life-mi.com

Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS

  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).

DRUG INTERACTIONS

  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

OVERDOSAGE
A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

.
.
.
.
.